logo
Top NHS GP reveals why spending too long on the toilet 'doom scrolling' can be disastrous for your health

Top NHS GP reveals why spending too long on the toilet 'doom scrolling' can be disastrous for your health

Daily Mail​8 hours ago

Smartphone-loving Britons are so attached to the devices that 60 per cent of us admit to using them while sitting on the toilet.
But scrolling on the loo for minutes on end could trigger a host of health problems, one top NHS GP has warned.
According to Dr Punam Krishan, who appears on BBC Morning Live, these include haemorrhoids, also known as piles, a weakened pelvic floor—triggering continence issues—and, in extreme cases, lead to a painful condition called rectal prolapse.
Haemorrhoids are swollen blood vessels in the back passage that can cause itching, discomfort, bleeding, and a persistent feeling of needing to pass stool.
Though often dismissed as minor or embarrassing, haemorrhoids are extremely common—affecting an estimated one in three adults in the UK at some point.
And the increase in prolonged toilet sitting, often coupled with mobile phone use, is quietly contributing to a rise in cases, Dr Krishnan said.
In an Instagram video posted to her 100,000 plus followers the resident doctor on BBC Morning Live said sitting on the loo for too long 'puts constant pressure on veins' and tissues of the lower rectum.
Over time, this can lead to the swelling and inflammation that characterise haemorrhoids.
View this post on Instagram
A post shared by Dr Punam Krishan (@drpunamkrishan)
In some cases, the pressure may also contribute to the weakening of muscles that support the rectum and anus, setting the stage for more serious complications.
One of these is rectal prolapse, a condition in which the rectum becomes stretched and begins to protrude from the anus, she said.
While less common, rectal prolapse is far more serious and often requires surgical intervention.
She added: 'Long sitting spells actually slows down the flood flow to the leg. Over time that can increase your risk of developing varicose vein.'
It is also 'really bad' for your pelvic floor as 'straining on the toilet put pressure on your deep muscles that support your bladder and your bowel,' she said.
'In loads of countries people still squat to poo and there is a really good reason for doing that.
'Squatting naturally lines everything up. It changes the angle between your bowel and your bum so it is easier to go without having to strain.
'And actually in places where squatting is still the norm, people tend to have fewer problems with piles and constipation.'
She added: 'When you go to the toilet, do your business, wash your hands and get out. Aim to keep it under ten minutes.'
Although there is no universally agreed 'safe' length of time to spend on the toilet, most gastroenterologists agree that if a bowel movement doesn't happen within five to ten minutes, it's best to get up, move around and try again later.
Going for a short walk or gently moving the body can help stimulate bowel motility more naturally, without the need to strain.
Dietary habits also play a role. Low-fibre diets, dehydration and a sedentary lifestyle can all contribute to constipation and harder stools, which increase the likelihood of straining.
Doctors recommend eating more fibre-rich foods such as fruit, vegetables, beans and whole grains, as well as drinking plenty of water throughout the day.
Physical activity, even just light daily movement, can also improve digestion and reduce the chances of constipation.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Poll suggests support for better end-of-life care over assisted dying Bill
Poll suggests support for better end-of-life care over assisted dying Bill

Powys County Times

time27 minutes ago

  • Powys County Times

Poll suggests support for better end-of-life care over assisted dying Bill

More than two thirds of people feel the assisted dying Bill should be replaced with a plan for better end-of-life care, according to a survey published days ahead of a major vote on the issue. The polling, commissioned by a group opposed to assisted dying being legalised, 'blows apart the arguments that the public are desperate' for a change in the law, a campaigner claimed. Bill sponsor Kim Leadbeater said last week that MPs should not have to choose between supporting assisted dying or palliative care as it is not an 'either/or' conversation for dying people. She said palliative care and assisted dying 'can and do work side by side to give terminally-ill patients the care and choice they deserve in their final days', and urged MPs to support 'all options available to terminally ill people'. An amendment to the Bill, requiring the Health Secretary to publish an assessment of the availability, quality and distribution of palliative and end-of-life care one year after the Bill passing into law, could be voted on on Friday. Friday is also set to be the Terminally Ill Adults (End of Life) Bill's third reading stage, which is likely to see the overall Bill voted on for the first time since November's historic yes vote, when a majority of 55 supported the principle of assisted dying for England and Wales. The latest polling, commissioned by Care Not Killing and carried out by British Polling Council member Whitestone, saw 2,089 UK adults surveyed online between May 30 and June 1. Respondents, who are said to have been weighted to be a representative sample, were told of concerns raised by the Royal Colleges of Physicians and Psychiatrists and the Association for Palliative Medicine about the Bill in its current form as well as opposition from disability campaigners. In this context, they were asked about replacing the Bill with a plan to improve and invest in palliative care – to which 69% agreed, and about a Royal Commission being set up to consider and make recommendations for a holistic end-of-life and palliative care service – with which 61% agreed. Almost two thirds (65%) said the Government's priority should be sorting out palliative and social care before changing the law – down very slightly from 66% last year. Gordon Macdonald, chief executive of Care Not Killing, said: 'This major new poll blows apart the arguments that the public are desperate for a so-called assisted dying law. 'The public want the Government and MPs to focus on fixing the NHS and palliative care which they know are broken. After all one in four Brits who would benefit from palliative care aren't currently receiving it, while in many places services are piecemeal, part-time or facing cuts.' It comes as former prime minister Gordon Brown repeated his opposition to assisted dying. Writing in the Guardian, he said: 'It has become clear that whatever views people hold on the principle, passing the terminally ill adults (end of life) bill into law would privilege the legal right to assisted dying without guaranteeing anything approaching an equivalent right to high-quality palliative care for those close to death.' He said MP's personal preferences 'cannot be separated off from the duties they have as members of a community to ensure that the way we treat the dying reflects the values of a decent, compassionate country'. He added: 'That should mean upholding the role of the medical professions as care-givers, and exclusively care-givers; avoiding the possibility of private profiteering by legal-medical consortiums which might well commercialise assisted dying as a lucrative business; safeguarding vulnerable people about whose fate the royal medical colleges have all expressed concern; preventing unacceptable coercive pressures that can be brought to bear on disabled people, and those who are incapacitated or mentally stressed; and thus showing that as a society we value life above death.' Dozens of Labour MPs called for Friday's overall vote to be delayed, asking for more time to scrutinise a Bill they brand as 'perhaps the most consequential piece of legislation that has appeared before the House in generations'. Writing to Commons leader Lucy Powell, they said: 'We implore you as the Leader of the House to allocate more Parliamentary time to the scrutiny of this Bill, the valid concerns that members have about its implementation, and the consequences it could have on vulnerable populations.' A Government spokesperson said: 'This Bill has been brought as a Private Members' Bill. The amount of time for debate is therefore a matter for the House.' The Bill's sponsor, Labour MP Kim Leadbeater, has repeatedly stated that her proposed legislation has been strengthened since it was first introduced last year, insisting it is subject to robust safeguards. Medical staff are among some of the MPs who back the Bill. As it stands, the proposed legislation would allow terminally-ill adults in England and Wales, with fewer than six months to live, to apply for an assisted death, subject to approval by two doctors and a panel featuring a social worker, senior legal figure and psychiatrist. MPs are entitled to have a free vote on the Bill and any amendments, meaning they decide according to their conscience rather than along party lines. Prime Minister Sir Keir Starmer voted in favour of the Bill last year, but said the Government remains neutral on the issue.

Genetic testing study to boost medication response starts in Glasgow
Genetic testing study to boost medication response starts in Glasgow

South Wales Argus

time28 minutes ago

  • South Wales Argus

Genetic testing study to boost medication response starts in Glasgow

The landmark trial will recruit up to 4,000 patients over the next two years in the NHS Greater Glasgow and Clyde area, to investigate how an individual's genetic profile affects their response to 60 common medications. It is hoped the Phoenix Study will to lead to wider implementation of genetic testing across Scotland, making 'precision medicine' routine, for the first time. Researchers hope it will pave the way for tailored prescribing across cardiology, stroke, surgery, orthopaedics, geriatrics, gynaecology, ENT, rheumatology, respiratory, neurology, psychiatry and other specialities. The trial will take place at the Queen Elizabeth University Hospital (QEUH) in Glasgow. Pharmacogenomics (PGx) – the study of how genes influence individual responses to drugs – has not been routinely used in clinical practice in the UK, amid hopes evidence will lead to change. Genetic test results will be sent to clinicians, allowing for treatment decisions to be adjusted, and patients will be followed up regularly to monitor the effects of any changes, to ensure they receive the highest standard of care. The trial is due to test 'precision medicine' for the first time in the UK (Julien Behal/PA) Patients will undergo a simple genetic test to analyse their DNA and the results, returned within days, will help doctors determine whether each patient is receiving the most suitable drug and dosage based on their genetic make-up. Around 15% are expected to carry genetic variants that may reduce the effectiveness of a medication or increase the risk of side-effects. In some cases, the prescribed drug may be ineffective, or a different dosage may be needed. The trial is open to adult in-patients in the QEUH and patients will be randomly assigned to either receive the pharmacogenomic test immediately, or at three months, which will allow the researchers to establish evidence of benefit. Without prior testing, these issues can go unnoticed, often leading to a trial-and-error approach to treatment, according to researchers. It is led by Sandosh Padmanabhan, Pontecorvo chair of Pharmacogenomics at the University of Glasgow, in partnership with the University of Glasgow's Living Laboratory, the NHSGGC-hosted West of Scotland Innovation Hub, and industry partners MyDNA and Agena Bioscience. Patient Eric Balish was asked to take part by consultants, after having a heart attack and subsequent surgery. He was immediately prescribed clopidogrel, one of the 60 drugs included in the study, but has since had his medication changed a number of times. Mr Balish said: 'I knew a bit about personalised medicine previously, and so when I was asked to take part in the Phoenix Study I was happy to do it. 'If you're asked to participate and support long-term research like this, then it's no great hardship to give something back and just do the right thing. I am hopeful my information can be of use to the trial and in the future.' Prof Padmanabhan, a consultant at the QEUH, said: 'Physicians and pharmacists increasingly recognise that PGx-informed prescribing and dispensing improves both the efficacy and safety of drug treatment. 'The primary goal of this trial is to evaluate the clinical and health-economic impact of PGx-guided prescribing. 'Specifically, we want to determine if a PGx-guided approach to prescribing can significantly reduce the incidence and severity of drug related side-effects and/or treatment failures. 'This evaluation will compare the outcomes of participants who receive PGx-guided medication management to those receiving standard care.' Dr Katriona Brooksbank, research and innovation lead for NHSGGC and the West of Scotland Innovation Hub, said: 'We are incredibly excited to be supporting this trial, which could have a major impact on the treatments patients are prescribed based on their own genetics. 'It will put precision medicine into action as researchers look to determine how a person's own genetic make-up can affect the drugs they are given as treatments. 'This could allow clinicians to reduce adverse reactions and side effects, ensuring the best possible outcomes for patients.' Allan Sheffield, co-founder of MyDNA, said: 'For MyDNA, the Phoenix Study embodies the future of healthcare. 'Our unique combination of pharmacogenomic clinical decision support and in-house Gene by Gene accredited testing empowers clinicians to move beyond guesswork. 'This trial will demonstrate the profound impact of precision medicine, paving the way for a future where this approach routinely drives better patient outcomes.'

Genetic testing study to boost medication response starts in Glasgow
Genetic testing study to boost medication response starts in Glasgow

Glasgow Times

time29 minutes ago

  • Glasgow Times

Genetic testing study to boost medication response starts in Glasgow

The landmark trial will recruit up to 4,000 patients over the next two years in the NHS Greater Glasgow and Clyde area, to investigate how an individual's genetic profile affects their response to 60 common medications. It is hoped the Phoenix Study will to lead to wider implementation of genetic testing across Scotland, making 'precision medicine' routine, for the first time. Researchers hope it will pave the way for tailored prescribing across cardiology, stroke, surgery, orthopaedics, geriatrics, gynaecology, ENT, rheumatology, respiratory, neurology, psychiatry and other specialities. The trial will take place at the Queen Elizabeth University Hospital (QEUH) in Glasgow. Pharmacogenomics (PGx) – the study of how genes influence individual responses to drugs – has not been routinely used in clinical practice in the UK, amid hopes evidence will lead to change. Genetic test results will be sent to clinicians, allowing for treatment decisions to be adjusted, and patients will be followed up regularly to monitor the effects of any changes, to ensure they receive the highest standard of care. The trial is due to test 'precision medicine' for the first time in the UK (Julien Behal/PA) Patients will undergo a simple genetic test to analyse their DNA and the results, returned within days, will help doctors determine whether each patient is receiving the most suitable drug and dosage based on their genetic make-up. Around 15% are expected to carry genetic variants that may reduce the effectiveness of a medication or increase the risk of side-effects. In some cases, the prescribed drug may be ineffective, or a different dosage may be needed. The trial is open to adult in-patients in the QEUH and patients will be randomly assigned to either receive the pharmacogenomic test immediately, or at three months, which will allow the researchers to establish evidence of benefit. Without prior testing, these issues can go unnoticed, often leading to a trial-and-error approach to treatment, according to researchers. It is led by Sandosh Padmanabhan, Pontecorvo chair of Pharmacogenomics at the University of Glasgow, in partnership with the University of Glasgow's Living Laboratory, the NHSGGC-hosted West of Scotland Innovation Hub, and industry partners MyDNA and Agena Bioscience. Patient Eric Balish was asked to take part by consultants, after having a heart attack and subsequent surgery. He was immediately prescribed clopidogrel, one of the 60 drugs included in the study, but has since had his medication changed a number of times. Mr Balish said: 'I knew a bit about personalised medicine previously, and so when I was asked to take part in the Phoenix Study I was happy to do it. 'If you're asked to participate and support long-term research like this, then it's no great hardship to give something back and just do the right thing. I am hopeful my information can be of use to the trial and in the future.' Prof Padmanabhan, a consultant at the QEUH, said: 'Physicians and pharmacists increasingly recognise that PGx-informed prescribing and dispensing improves both the efficacy and safety of drug treatment. 'The primary goal of this trial is to evaluate the clinical and health-economic impact of PGx-guided prescribing. 'Specifically, we want to determine if a PGx-guided approach to prescribing can significantly reduce the incidence and severity of drug related side-effects and/or treatment failures. 'This evaluation will compare the outcomes of participants who receive PGx-guided medication management to those receiving standard care.' Dr Katriona Brooksbank, research and innovation lead for NHSGGC and the West of Scotland Innovation Hub, said: 'We are incredibly excited to be supporting this trial, which could have a major impact on the treatments patients are prescribed based on their own genetics. 'It will put precision medicine into action as researchers look to determine how a person's own genetic make-up can affect the drugs they are given as treatments. 'This could allow clinicians to reduce adverse reactions and side effects, ensuring the best possible outcomes for patients.' Allan Sheffield, co-founder of MyDNA, said: 'For MyDNA, the Phoenix Study embodies the future of healthcare. 'Our unique combination of pharmacogenomic clinical decision support and in-house Gene by Gene accredited testing empowers clinicians to move beyond guesswork. 'This trial will demonstrate the profound impact of precision medicine, paving the way for a future where this approach routinely drives better patient outcomes.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store